Type 2 Diabetes | Access and Reimbursement | US | 2016

Publish date: July 2016

Login to access report

The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S. endocrinologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. The interaction between payers and physicians, including how reimbursement decisions impact prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in the second line following metformin monotherapy.